Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Digital health tools

Topic: Risk, prevention and care in population studies

Introduction Artificial intelligence (AI) and neuroimaging offer new opportunities for diagnosis and prognosis of dementia. Methods We systematically reviewed studies reporting AI for neuroimaging in diagnosis and/or prognosis of cognitive neurodegenerative diseases. Results A total of 255 studies were identified. Most studies relied on the Alzheimer's Disease Neuroimaging Initiative dataset. Algorithmic classifiers were the most commonly used AI method (48%) and discriminative models performed best for differentiating Alzheimer's disease from controls. The accuracy of algorithms varied with the patient cohort, imaging modalities, and stratifiers used. Few studies performed validation in an independent cohort. Discussion The literature has several methodological limitations including lack of sufficient algorithm development descriptions and standard definitions. We make recommendations to improve model validation including addressing key clinical questions, providing sufficient description of AI methods and validating findings in independent datasets. Collaborative approaches between experts in AI and medicine will help achieve the promising potential of AI tools in practice. Highlights There has been a rapid expansion in the use of machine learning for diagnosis and prognosis in neurodegenerative disease Most studies (71%) relied on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset with no other individual dataset used more than five times There has been a recent rise in the use of more complex discriminative models (e.g., neural networks) that performed better than other classifiers for classification of AD vs healthy controls We make recommendations to address methodological considerations, addressing key clinical questions, and validation We also make recommendations for the field more broadly to standardize outcome measures, address gaps in the literature, and monitor sources of bias.

Key findings

Why it matters

This review of 255 studies on AI and brain imaging for dementia found that most (71%) relied on a single research dataset (ADNI) and that few tested their models on an independent group of patients. Discriminative models performed best at telling Alzheimer's disease apart from healthy controls, but accuracy varied with the patients, scan types and methods used. The authors call for clearer reporting and independent validation before these tools reach practice. The review concerns diagnosis and prognosis only, not treatment or prevention.

Study details

How this study scored 71/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 71 of 100.71 of 100 points earned29 not earned

Published in a leading specialty journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question (from PubMed type “Systematic Review”)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 2 / 4 255 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 A review of other studies — randomisation is not credited here
Times cited 5 / 7 Cited 122 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 24.4 citations a year over 5 year(s) since 2023
Impact for its field and year 3 / 6 Cited 7.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 9 other studies in this library
Still being cited 3 / 4 Cited 115 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Timothy Rittman: h-index 47 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 28 institution(s) in 9 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37563912)
Free to read 0 / 2 Behind a paywall — scores zero
Total 71 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Borchert, R. J., Azevedo, T., Badhwar, A., Bernal, J., Betts, M., Bruffaerts, R., et al. (2023). Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13412

Vancouver

Borchert RJ, Azevedo T, Badhwar A, Bernal J, Betts M, Bruffaerts R, et al. Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023. doi:10.1002/alz.13412. PMID: 37563912.

BibTeX

@article{borchert2023-37563912,
  author  = {Borchert, R. J. and Azevedo, T. and Badhwar, A. and Bernal, J. and Betts, M. and Bruffaerts, R. and Burkhart, M. C. and Dewachter, I. and others},
  title   = {{Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2023},
  doi     = {10.1002/alz.13412},
  pmid    = {37563912},
  url     = {https://doi.org/10.1002/alz.13412}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 29.

Later studies that cite this one

9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Digital health tools

Similar studies

More on Digital health tools

See all studies in Digital health tools →